7 completed, 3 terminated, 1 active not recruiting. 11 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 7, Terminated 3, Active not recruiting 1 |
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Terminated 1 |
Follow Prothya Biosolutions: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Add-on Intravenous Immunoglobulins in Early Myositis Immune Globulin Intravenous (Human), Placebo - Inflammatory Myopathy, Idiopathic, Dermatomyositis | Phase 2 / Phase 3 | Active not recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 44 | 2021-09-13 | 2026-02-27 |
| Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study) ConvP, FFP - Covid19 | Phase 3 | Terminated | Erasmus Medical Center | 420 | 2020-10-12 | 2022-04-01 |
| Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study) Convalescent plasma - COVID-19 | Phase 2 / Phase 3 | Terminated | Erasmus Medical Center | 86 | 2020-04-08 | 2022-04-01 |
| Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml Intravenous immunoglobulin infusion - Primary Immunodeficiency | Phase 3 | Completed | Prothya Biosolutions | 23 | 2013-12-01 | 2015-04-06 |
| In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II C1-esterase inhibitor, Endotoxin - Innate Immune Response, Endotoxemia | Phase 3 | Completed | Radboud University Medical Center | 20 | 2013-09-01 | 2014-12-02 |
| Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture C1-esterase inhibitor, Saline 0.9% - Trauma, Inflammation | Phase 3 | Terminated | UMC Utrecht | 11 | 2012-04-01 | 2015-02-04 |
| Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy Intravenous Immunoglobulins, plasma volume expander - Myocardial Diseases, Parvovirus B19, Human | Phase 3 | Completed | Prothya Biosolutions | 50 | 2009-11-01 | 2018-08-29 |
| C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema C1 inhibitor concentrate (C1-esteraseremmer-N) - Angioedema | Phase 2 / Phase 3 | Completed | Prothya Biosolutions | 6 | 2006-11-01 | 2009-05-04 |
| C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema C1 inhibitor concentrate (C1-esteraseremmer-N) - Angioedema | Phase 3 | Completed | Prothya Biosolutions | 15 | 2006-02-01 | 2009-05-04 |
| Efficacy and Safety of IVIG-L in ITP Patients IVIG-L - Purpura, Thrombocytopenic, Idiopathic | Phase 3 | Completed | Prothya Biosolutions | 20 | 2001-10-01 | 2006-01-31 |
| Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients IVIG-L - Hypogammaglobulinemia | Phase 2 / Phase 3 | Completed | Prothya Biosolutions | 15 | 2001-05-01 | 2007-04-19 |
Acquired angioedema (2) · Angioedema (2) · COVID-19 (2) · Hereditary Angioedema Types I and II (2) · Inflammation (2) · Sepsis (2) · Agammaglobulinemia (1) · Angioedemas, Hereditary (1) · Antisynthetase syndrome (1) · Cardiomyopathies (1) · Dermatomyositis (1) · Endotoxemia (1) · Multiple Organ Failure (1) · Myositis (1) · Polymyositis (1)
Complement C1 Inhibitor Protein (2) · Immunoglobulins, Intravenous (2) · Sodium Chloride (2) · Endotoxins (1) · Plasma Substitutes (1) · let-363 protein, C elegans (1)
Netherlands (10) · Poland (1)
Bart Rijnders, MD, PhD (2) · M. M. Levi, Prof. Dr. (2) · F P Kroon, PhD, MD (1) · Hans Hoeven, Prof (1) · Luke P Leenen, MD, PhD (1) · P FW Strengers, MD (1) · S Heymans, PhD, MD (1)
PMID 21988742, PMID 28515092, PMID 33044747, PMID 33347677, PMID 34013969, PMID 35546145, PMID 36734509, PMID 37162745